SARS-CoV-2 papain-like protease (PLpro) plays crucial roles in viral maturation and immune response dysregulation, making it a promising drug target. This study screened a drug library, identifying GRL0617 as a potent PLpro inhibitor. The co-crystal structure of SARS-CoV-2 PLpro with GRL0617 reveals a non-covalent interaction within the USP domain. NMR data demonstrates GRL0617 blocks ISG15 C-terminus binding to PLpro, highlighting this pocket as a crucial hot spot for antiviral drug development.
Publisher
Nature Communications
Published On
Jan 20, 2021
Authors
Ziyang Fu, Bin Huang, Jinle Tang, Shuyan Liu, Ming Liu, Yuxin Ye, Zhihong Liu, Yuxian Xiong, Wenning Zhu, Dan Cao, Jihui Li, Xiaogang Niu, Huan Zhou, Yong Juan Zhao, Guoliang Zhang, Hao Huang
Tags
SARS-CoV-2
PLpro inhibitor
GRL0617
antiviral drug
structural biology
NMR
immune response
Related Publications
Explore these studies to deepen your understanding of the subject.